Ezio Bonvini

This inventor holds 43 USPTO granted patents and 33 published patent applications, plus 9 CIPO patents and 15 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Macrogenics, Inc., Other. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ezio Bonvini. Retrieved from https://idiyas.com/inventor/ezio-bonvini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 43 (Patent Applications = 33)

% Patents Active = 83.7

CIPO Patents = 9 (Patent Applications = 19)

EPO Patents = 15 (Patent Applications = 39)

Average Co-Inventor Count = 5.4

ph-index = 10

Forward Citations = 395(Granted Patents)

Location History:

Rockville, MD (US) (2012 - 2024)
Potomac, MD (US) (2016 - 2024)

Company Filing History:

42 out of 133

Macrogenics, Inc.

patents

1 out of 834,659

Other

patents

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

PD-1 Binding Molecules

Bispecific Antibodies

CD137 Binding Molecules

HER2/neu Antibodies

Combination Therapy

Tri-Specific Binding Molecules

Immunoreactivity

Monovalent Diabodies

Cancer Antigens

Antibody Drug Conjugates

Polypeptide Containing Molecules

Immunosuppressive Monoclonal Antibodies

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12600779 - LAG-3-Binding Molecules and Methods of Use Thereof (2026-04-14),

2. 12534531 - PD-1-BINDING MOLECULES AND METHODS OF USE THEREOF (2026-01-27),

3. 12435155 - CD137 binding molecules and uses thereof (2025-10-07),

4. 12024569 - HER2/neu-specific antibodies and methods of using same (2024-07-02),

5. 11942149 - Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof (2024-03-26),

6. 11858991 - LAG-3-binding molecules and methods of use thereof (2024-01-02),

7. 11840571 - Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4 (2023-12-12),

8. 11820818 - Multi-chain polypeptide-containing tri-specific binding molecules (2023-11-21),

9. 11697684 - Tri-specific binding molecules that specifically bind to multiple cancer antigens (2023-07-11),

10. 11685781 - Variant CD3-binding domains and their use in combination therapies for the treatment of disease (2023-06-27),

11. 11639386 - Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof (2023-05-02),

12. 11623959 - PD-1-binding molecules and methods of use thereof (2023-04-11),

13. 11591400 - B7-H3 directed antibody drug conjugates (2023-02-28),

14. 11459394 - Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof (2022-10-04),

15. 11384149 - Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof (2022-07-12),

Title: The Innovative Contributions of Ezio Bonvini in Biopharmaceuticals

Introduction

Ezio Bonvini, a prolific inventor based in Potomac, MD, has made significant strides in the field of biopharmaceuticals, particularly focusing on cancer therapies. With an impressive portfolio of 40 patents, his work emphasizes the development of novel therapeutic antibodies aimed at targeting specific antigens involved in various diseases.

Latest Patents

Among his latest innovations are two noteworthy patents. The first patent pertains to HER2/neu-specific antibodies and methods of using them. This invention highlights antibodies that selectively bind to HER2/neu, specifically the chimeric 4D5 antibodies exhibiting reduced glycosylation properties compared to their known counterparts. The application of these antibodies spans numerous medical domains, including diagnostics, prognostics, and therapeutic strategies for conditions such as cancer, autoimmune diseases, inflammatory disorders, and infectious diseases.

The second significant patent involves bispecific binding molecules that can simultaneously bind CD137 and tumor antigens. This invention focuses on creating binding molecules, particularly bispecific tetravalent diabodies, which include multiple polypeptide chains with distinct epitope-binding sites for both CD137 and tumor antigens. The pharmaceutical compositions derived from these molecules promise advancements in the treatment of cancer and other diseases.

Career Highlights

Ezio Bonvini has had a notable career with companies such as Macrogenics, Inc., where he has applied his expertise to develop cutting-edge therapies. His dedication to research and innovation has significantly impacted the biopharmaceutical landscape.

Collaborations

Throughout his career, Bonvini has collaborated with several esteemed professionals, including Leslie Sydnor Johnson and Paul A. Moore. These collaborations reflect a commitment to advancing therapeutic approaches through teamwork and shared expertise.

Conclusion

Ezio Bonvini's contributions to inventing targeted therapies illustrate the vital role of innovation in addressing complex health challenges. His patents not only enhance our understanding of antibody applications but also pave the way for future advancements in the diagnosis and treatment of various diseases.

Profile summary based on public USPTO records.